Hereditary ovarian cancer and two-compartment tumor metabolism: Epithelial loss of BRCA1 induces hydrogen peroxide production, driving oxidative stress and NFκB activation in the tumor stroma

Cell Cycle

Volumn 11, Issue 22, 2012, Pages 4152-4166

  Martinez Outschoorn, Ubaldo E ^a,b   Balliet, Renee M ^a   Lin, Zhao ^a   Whitaker Menezes, Diana ^a   Howell, Anthony ^c   Sotgia, Federica ^a,c   Lisanti, Michael P ^a,b,c  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Autophagy; BRCA1 mutations; Caveolin 1 (Cav 1); Hereditary ovarian cancer; Hydrogen peroxide; MCT4; Mitophagy; NF B activation; Oxidative stress; Tumor metabolism

Indexed keywords

ACETYLCYSTEINE; BRCA1 PROTEIN; CAVEOLIN 1; HISTONE H2AX; HYDROGEN PEROXIDE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR RELA;

APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER CELL; CATABOLISM; CONTROLLED STUDY; FAMILIAL CANCER; FEMALE; FIBROBLAST; GENE OVEREXPRESSION; GLYCOLYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; MITOPHAGY; OVARY CANCER; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; STROMA CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION;

EID: 84869487125     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.22226     Document Type: Article

References (97)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62:10-29; PMID:22237781; http://dx.doi.org/10.3322/caac.20138.
2. Narod SA, Dubé MP, Klijn J, Lubinski J, Lynch HT, Ghadirian P, et al. Oral contraceptives and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 2002; 94:1773-9; PMID:12464649; http://dx.doi.org/10.1093/jnci/94.23.1773.
3. Darbary H, Stoler DL, Anderson GR. Family cancer syndromes: inherited deficiencies in systems for the maintenance of genomic integrity. [vii.]. Surg Oncol Clin N Am 2009; 18:1-17, vii; PMID:19056039; http://dx.doi.org/10.1016/j. soc.2008.08.001.
4. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway. J Clin Oncol 2008; 26:3259-67; PMID:18591560; http://dx.doi.org/10.1200/JCO.2007.11.3902.
5. Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003; 72:1117-30; PMID:12677558; http://dx.doi.org/10.1086/375033.
6. Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer 2012; 12:68-78; PMID:22193408; http://dx.doi.org/10.1038/nrc3181.
7. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010; 11:138-48; PMID:20029420; http://dx.doi.org/10.1038/nrm2831.
8. Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med 2008; 359:2143-53; PMID:19005198; http://dx.doi.org/10.1056/NEJMra0802968.
9. Rubin SC, Benjamin I, Behbakht K, Takahashi H, Morgan MA, LiVolsi VA, et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335:1413-6; PMID:8875917; http://dx.doi.org/10.1056/NEJM199611073351901.
10. Boyd J, Sonoda Y, Federici MG, Bogomolniy F, Rhei E, Maresco DL, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283:2260-5; PMID:10807385; http://dx.doi.org/10.1001/jama.283.17.2260.
11. Majdak EJ, De Bock GH, Brozek I, Perkowska M, Ochman K, Debniak J, et al. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases - preliminary report. Eur J Cancer 2005; 41:143-50; PMID:15617999; http://dx.doi.org/10.1016/j.ejca.2004. 10.011.
12. Quinn JE, Carser JE, James CR, Kennedy RD, Harkin DP. BRCA1 and implications for response to chemotherapy in ovarian cancer. Gynecol Oncol 2009; 113:134-42; PMID:19168207; http://dx.doi.org/10.1016/j.ygyno.2008.12.015.
13. Ben David Y, Chetrit A, Hirsh-Yechezkel G, Friedman E, Beck BD, Beller U, et al.; National Israeli Study of Ovarian Cancer. Effect of BRCA mutations on the length of survival in epithelial ovarian tumors. J Clin Oncol 2002; 20:463-6; PMID:11786575; http://dx.doi.org/10.1200/JCO.20.2.463.
14. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCAassociated ovarian carcinoma. Cancer 2003; 97:2187-95; PMID:12712470; http://dx.doi.org/10.1002/cncr.11310.
15. Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M, et al.; Polish Hereditary Breast Cancer Consortium. Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers. Breast Cancer Res Treat 2008; 108:289-96; PMID:17492376; http://dx.doi.org/10.1007/s10549-007- 9600-1.
16. Easton DF, Deffenbaugh AM, Pruss D, Frye C, Wenstrup RJ, Allen-Brady K, et al. A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet 2007; 81:873-83; PMID:17924331; http://dx.doi.org/10.1086/ 521032.
17. Yoshikawa K, Honda K, Inamoto T, Shinohara H, Yamauchi A, Suga K, et al. Reduction of BRCA1 protein expression in Japanese sporadic breast carcinomas and its frequent loss in BRCA1-associated cases. Clin Cancer Res 1999; 5:1249-61; PMID:10389907.
18. Wilson CA, Ramos L, Villaseñor MR, Anders KH, Press MF, Clarke K, et al. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999; 21:236-40; PMID:9988281; http://dx.doi.org/ 10.1038/6029.
19. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2006; 16(Suppl 1):166-71; PMID:16515585; http://dx.doi.org/10.1111/j.1525-1438.2006.00504.x.
20. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev Cancer 2004; 4:814-9; PMID:15510162; http://dx.doi.org/10.1038/ nrc1457.
21. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/10. 1038/nature10166.
22. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCA1 and BRCA2 in ovarian cancer. J Natl Cancer Inst 2002; 94:1396-406; PMID:12237285; http://dx.doi.org/10.1093/jnci/94.18.1396.
23. Fong MY, McDunn J, Kakar SS. Identification of metabolites in the normal ovary and their transformation in primary and metastatic ovarian cancer. PLoS One 2011; 6:e19963; PMID:21625518; http://dx.doi.org/10.1371/journal.pone. 0019963.
24. Karihtala P, Soini Y, Vaskivuo L, Bloigu R, Puistola U. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma. Int J Gynecol Cancer 2009; 19:1047-51; PMID:19820366; http://dx.doi.org/10.1111/IGC.0b013e3181ad0f0d.
25. Esteve JM, Armengod ME, Knecht E. BRCA1 negatively regulates formation of autophagic vacuoles in MCF-7 breast cancer cells. Exp Cell Res 2010; 316:2618-29; PMID:20599945; http://dx.doi.org/10.1016/j.yexcr.2010.06.019.
26. Bae I, Fan S, Meng Q, Rih JK, Kim HJ, Kang HJ, et al. BRCA1 induces antioxidant gene expression and resistance to oxidative stress. Cancer Res 2004; 64:7893-909; PMID:15520196; http://dx.doi.org/10.1158/0008-5472.CAN-04-1119.
27. Saha T, Rih JK, Rosen EM. BRCA1 down-regulates cellular levels of reactive oxygen species. FEBS Lett 2009; 583:1535-43; PMID:19364506; http://dx.doi.org/10.1016/j.febslet.2009.04.005.
28. Rodriguez H, Jaruga P, Leber D, Nyaga SG, Evans MK, Dizdaroglu M. Lymphoblasts of women with BRCA1 mutations are deficient in cellular repair of 8,5′-Cyclopurine-2′-deoxynucleosides and 8-hydroxy-2′- deoxyguanosine. Biochemistry 2007; 46:2488- 96; PMID:17288454; http://dx.doi.org/10.1021/bi062022p.
29. Dziaman T, Huzarski T, Gackowski D, Rozalski R, Siomek A, Szpila A, et al. Elevated level of 8-oxo-7,8-dihydro-2′-deoxyguanosine in leukocytes of BRCA1 mutation carriers compared to healthy controls. Int J Cancer 2009; 125:2209-13; PMID:19623658; http://dx.doi.org/10.1002/ijc.24600.
30. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8:3984-4001; PMID:19923890; http://dx.doi.org/10.4161/cc.8.23.10238.
31. Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial "lactate shuttle"in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10:1772-83; PMID:21558814; http://dx.doi.org/10.4161/cc.10.11.15659.
32. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011; 17:1498-503; PMID:22037646; http://dx.doi.org/10.1038/nm.2492.
33. Koukourakis MI, Giatromanolaki A, Harris AL, Sivridis E. Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: a metabolic survival role for tumor-associated stroma. Cancer Res 2006; 66:632-7; PMID:16423989; http://dx.doi.org/10.1158/0008-5472.CAN-05-3260.
34. Fiaschi T, Marini A, Giannoni E, Taddei ML, Gandellini P, De Donatis A, et al. Reciprocal Metabolic Reprogramming through Lactate Shuttle Coordinately Influences Tumor-Stroma Interplay. Cancer Res 2012; PMID:22850421; http://dx.doi.org/10.1158/0008-5472.CAN-12-1949.
35. Giatromanolaki A, Koukourakis MI, Koutsopoulos A, Mendrinos S, Sivridis E. The metabolic interactions between tumor cells and tumor-associated stroma (TAS) in prostatic cancer. Cancer Biol Ther 2012; 13:13; PMID:22895074.
36. Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023-34; PMID:19411448; http://dx.doi.org/10.2353/ajpath.2009.080873.
37. Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, et al. Using the "reverse Warburg effect" to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012; 11:1108-17; PMID:22313602; http://dx.doi.org/10.4161/cc.11.6.19530.
38. Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, et al. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle 2011; 10:4250-5; PMID:22134245; http://dx.doi.org/10.4161/ cc.10.24.18551.
39. Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8:2420-4; PMID:19556867; http://dx.doi.org/10.4161/cc.8.15.9116.
40. Xia C, Meng Q, Liu LZ, Rojanasakul Y, Wang XR, Jiang BH. Reactive oxygen species regulate angiogenesis and tumor growth through vascular endothelial growth factor. Cancer Res 2007; 67:10823-30; PMID:18006827; http://dx.doi.org/ 10.1158/0008-5472.CAN-07-0783.
41. Saunders JA, Rogers LC, Klomsiri C, Poole LB, Daniel LW. Reactive oxygen species mediate lysophosphatidic acid induced signaling in ovarian cancer cells. Free Radic Biol Med 2010; 49:2058-67; PMID:20934509; http://dx.doi.org/10.1016/ j.freeradbiomed.2010.10.663.
42. Ralph SJ, Rodríguez-Enríquez S, Neuzil J, Saavedra E, Moreno-Sánchez R. The causes of cancer revisited: "mitochondrial malignancy" and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31:145-70; PMID:20206201; http://dx.doi.org/10.1016/j.mam.2010.02.008.
43. Cui X. Reactive oxygen species: the achilles' heel of cancer cells? Antioxid Redox Signal 2012; 16:1212-4; PMID:22304673; http://dx.doi.org/10.1089/ ars.2012.4532.
44. Enns L, Ladiges W. Mitochondrial redox signaling and cancer invasiveness. J Bioenerg Biomembr 2012; PMID:22886605; http://dx.doi.org/10.1007/s10863-012- 9467-7.
45. Martinez-Outschoorn UE, Balliet RM, Rivadeneira DB, Chiavarina B, Pavlides S, Wang C, et al. Oxidative stress in cancer associated fibroblasts drives tumorstroma co-evolution: A new paradigm for understanding tumor metabolism, the field effect and genomic instability in cancer cells. Cell Cycle 2010; 9:3256-76; PMID:20814239; http://dx.doi.org/10.4161/cc.9.16.12553.
46. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 2011; 10:2504-20; PMID:21778829; http://dx.doi.org/10.4161/cc.10.15.16585.
47. Ohkouchi S, Block GJ, Katsha AM, Kanehira M, Ebina M, Kikuchi T, et al. Mesenchymal stromal cells protect cancer cells from ROS-induced apoptosis and enhance the Warburg effect by secreting STC1. Mol Ther 2012; 20:417-23; PMID:22146344; http://dx.doi.org/10.1038/mt.2011.259.
48. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancera-ssociated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal 2012; 16:1264-84; PMID:21883043; http://dx.doi.org/10.1089/ars. 2011.4243.
49. Sivridis E, Giatromanolaki A, Koukourakis MI. Proliferating fibroblasts at the invading tumour edge of colorectal adenocarcinomas are associated with endogenous markers of hypoxia, acidity, and oxidative stress. J Clin Pathol 2005; 58:1033-8; PMID:16189147; http://dx.doi.org/10.1136/jcp.2005.026260.
50. Salazar H, Godwin AK, Daly MB, Laub PB, Hogan WM, Rosenblum N, et al. Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996; 88:1810-20; PMID:8961970; http://dx.doi.org/10.1093/jnci/88.24.1810.
51. DelloRusso C, Welcsh PL, Wang W, Garcia RL, King MC, Swisher EM. Functional characterization of a novel BRCA1-null ovarian cancer cell line in response to ionizing radiation. Mol Cancer Res 2007; 5:35-45; PMID:17259345; http://dx.doi.org/10.1158/1541-7786.MCR-06-0234.
52. Pilch DR, Sedelnikova OA, Redon C, Celeste A, Nussenzweig A, Bonner WM. Characteristics of gamma-H2AX foci at DNA double-strand breaks sites. Biochem Cell Biol 2003; 81:123-9; PMID:12897845; http://dx.doi.org/10.1139/o03-042.
53. Ullah MS, Davies AJ, Halestrap AP. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alphadependent mechanism. J Biol Chem 2006; 281:9030-7; PMID:16452478; http://dx.doi.org/10.1074/jbc.M511397200.
54. Bubici C, Papa S, Dean K, Franzoso G. Mutual crosstalk between reactive oxygen species and nuclear factorkappa B: molecular basis and biological significance. Oncogene 2006; 25:6731-48; PMID:17072325; http://dx.doi.org/10. 1038/sj.onc.1209936.
55. Martinez-Outschoorn UE, Trimmer C, Lin Z, Whitaker-Menezes D, Chiavarina B, Zhou J, et al. Autophagy in cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and NFκB activation in the tumor stromal microenvironment. Cell Cycle 2010; 9:3515-33; PMID:20855962; http://dx.doi.org/10.4161/cc.9.17.12928.
56. Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7:423-67; PMID:22077552; http://dx.doi. org/10.1146/annurev-pathol-011811-120856.
57. Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 2012; 227:490-8; PMID:22488553; http://dx.doi.org/10.1002/ path.4034.
58. Martinez-Outschoorn UE, Pavlides S, Whitaker-Menezes D, Daumer KM, Milliman JN, Chiavarina B, et al. Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle 2010; 9:2423-33; PMID:20562526; http://dx.doi.org/10.4161/cc.9.12.12048.
59. Cantuaria G, Magalhaes A, Penalver M, Angioli R, Braunschweiger P, Gomez-Marin O, et al. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. Gynecol Oncol 2000; 79:33-7; PMID:11006027; http://dx.doi.org/10.1006/gyno.2000.5910.
60. Yasuda M, Miyazawa M, Fujita M, Kajiwara H, Iida T, Hirasawa T, et al. Expression of hypoxia inducible factor-1alpha (HIF-1alpha) and glucose transporter-1 (GLUT-1) in ovarian adenocarcinomas: difference in hypoxic status depending on histological character. Oncol Rep 2008; 19:111-6; PMID:18097583.
61. Yoshida Y, Kurokawa T, Tsujikawa T, Okazawa H, Kotsuji F. Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16alpha-18F-fluoro-17beta-estradiol PET. J Ovarian Res 2009; 2:7; PMID:19527525; http://dx.doi.org/10.1186/1757-2215-2-7.
62. Nanni C, Rubello D, Farsad M, De Iaco P, Sansovini M, Erba P, et al. (18)F-FDG PET/CT in the evaluation of recurrent ovarian cancer: a prospective study on forty-one patients. Eur J Surg Oncol 2005; 31:792-7; PMID:15893908; http://dx.doi.org/10.1016/j.ejso.2005.02.029.
63. Airley R, Evans A, Mobasheri A, Hewitt SM. Glucose transporter Glut-1 is detectable in peri-necrotic regions in many human tumor types but not normal tissues: Study using tissue microarrays. Ann Anat 2010; 192:133-8; PMID:20395120; http://dx.doi.org/10.1016/j.aanat.2010.03.001.
64. Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9:2412-22; PMID:20562527; http://dx.doi.org/10.4161/cc.9.12.11989.
65. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Dürr P, et al. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol 2011; 25:503-15; PMID:21273445; http://dx.doi.org/10.1210/me.2010-0340.
66. Yao Q, Qu X, Yang Q, Good DA, Dai S, Kong B, et al. Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models. Mol Cancer 2009; 8:78; PMID:19781102; http://dx.doi.org/10.1186/ 1476-4598-8-78.
67. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3:97-137; PMID:19383374; http://dx.doi.org/10.1016/ j.molonc.2009.02.004.
68. Schrag D, Kuntz KM, Garber JE, Weeks JC. Life expectancy gains from cancer prevention strategies for women with breast cancer and BRCA1 or BRCA2 mutations. JAMA 2000; 283:617-24; PMID:10665701; http://dx.doi.org/10.1001/jama. 283.5.617.
69. Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 2006; 144:397-406; PMID:16549852.
70. Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol 2008; 26:1331-7; PMID:18268356; http://dx.doi.org/10.1200/ JCO.2007.13.9626.
71. Kang HJ, Hong YB, Kim HJ, Wang A, Bae I. Bioactive food components prevent carcinogenic stress via Nrf2 activation in BRCA1 deficient breast epithelial cells. Toxicol Lett 2012; 209:154-60; PMID:22192953; http://dx.doi.org/10.1016/j.toxlet.2011.12.002.
72. Dziaman T, Huzarski T, Gackowski D, Rozalski R, Siomek A, Szpila A, et al. Selenium supplementation reduced oxidative DNA damage in adnexectomized BRCA1 mutations carriers. Cancer Epidemiol Biomarkers Prev 2009; 18:2923-8; PMID:19843683; http://dx.doi.org/10.1158/1055-9965.EPI-09-0529.
73. Kowalska E, Narod SA, Huzarski T, Zajaczek S, Huzarska J, Gorski B, et al. Increased rates of chromosome breakage in BRCA1 carriers are normalized by oral selenium supplementation. Cancer Epidemiol Biomarkers Prev 2005; 14:1302-6; PMID:15894690; http://dx.doi.org/10.1158/1055-9965.EPI-03-0448.
74. Gifkins D, Olson SH, Paddock L, King M, Demissie K, Lu SE, et al. Total and individual antioxidant intake and risk of epithelial ovarian cancer. BMC Cancer 2012; 12:211; PMID:22656322; http://dx.doi.org/10.1186/1471-2407-12-211.
75. Goodman M, Bostick RM, Kucuk O, Jones DP. Clinical trials of antioxidants as cancer prevention agents: past, present, and future. Free Radic Biol Med 2011; 51:1068-84; PMID:21683786; http://dx.doi.org/10.1016/j.freeradbiomed.2011. 05.018.
76. Foulkes WD, Smith IE, Reis-Filho JS. Triple-negative breast cancer. N Engl J Med 2010; 363:1938-48; PMID:21067385; http://dx.doi.org/10.1056/ NEJMra1001389.
77. Baldwin RL, Nemeth E, Tran H, Shvartsman H, Cass I, Narod S, et al. BRCA1 promoter region hypermethylation in ovarian carcinoma: a population-based study. Cancer Res 2000; 60:5329-33; PMID:11034065.
78. Russell PA, Pharoah PD, De Foy K, Ramus SJ, Symmonds I, Wilson A, et al. Frequent loss of BRCA1 mRNA and protein expression in sporadic ovarian cancers. Int J Cancer 2000; 87:317-21; PMID:10897034; http://dx.doi.org/10.1002/1097- 0215(20000801)87:3〈317::AID-IJC2〉3.0.CO;2-B.
79. Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010; 28:3570-6; PMID:20606085; http://dx.doi.org/10.1200/JCO.2009.27. 2997.
80. Gillet JP, Calcagno AM, Varma S, Marino M, Green LJ, Vora MI, et al. Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anticancer drug resistance. Proc Natl Acad Sci USA 2011; 108:18708-13; PMID:22068913; http://dx.doi.org/10.1073/pnas.1111840108.
81. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, Provencher DM, et al. Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 2007; 46:872-85; PMID:17455221; http://dx.doi.org/10.1002/mc.20315.
82. Ramus SJ, Bobrow LG, Pharoah PD, Finnigan DS, Fishman A, Altaras M, et al. Increased frequency of TP53 mutations in BRCA1 and BRCA2 ovarian tumours. Genes Chromosomes Cancer 1999; 25:91-6; PMID:10337991; http://dx.doi.org/10. 1002/ (SICI)1098-2264(199906)25:2〈91::AIDGCC3〉3.0.CO;2-5.
83. Linger RJ, Kruk PA. BRCA1 16 years later: risk-associated BRCA1 mutations and their functional implications. FEBS J 2010; 277:3086-96; PMID:20608970; http://dx.doi.org/10.1111/j.1742-4658.2010.07735.x.
84. Martinez-Outschoorn UE, Lin Z, Trimmer C, Flomenberg N, Wang C, Pavlides S, et al. Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect: implications for PET imaging of human tumors. Cell Cycle 2011; 10:2504-20; PMID:21778829; http://dx.doi.org/10.4161/cc.10.15.16585.
85. Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011; 10:4047-64; PMID:22134189; http://dx.doi.org/10.4161/cc.10.23.18151.
86. Cannistra SA. Cancer of the ovary. N Engl J Med 2004; 351:2519-29; PMID:15590954; http://dx.doi.org/10.1056/NEJMra041842.
87. Furlan D, Carnevali I, Marcomini B, Cerutti R, Dainese E, Capella C, et al. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas. Clin Cancer Res 2006; 12:3329-36; PMID:16740754; http://dx.doi.org/10.1158/1078-0432.CCR-05-2679.
88. Lu KH, Bell DA, Welch WR, Berkowitz RS, Mok SC. Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors. Cancer Res 1998; 58:2328-30; PMID:9622067.
89. Gu J, Roth LM, Younger C, Michael H, Abdul-Karim FW, Zhang S, et al. Molecular evidence for the independent origin of extra-ovarian papillary serous tumors of low malignant potential. J Natl Cancer Inst 2001; 93:1147-52; PMID:11481386; http://dx.doi.org/10.1093/jnci/93.15.1147.
90. Wang J, Lin L, Parkash V, Schwartz PE, Lauchlan SC, Zheng W. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. Int J Cancer 2003; 103:328-34; PMID:12471615; http://dx.doi.org/10.1002/ijc.10848.
91. Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ. Field cancerization: why late "recurrent"ovarian cancer is not recurrent. Am J Obstet Gynecol 1998; 178:641-9; PMID:9579425; http://dx.doi.org/10.1016/ S0002-9378(98)70473-9.
92. Slaughter DP. Multicentric origin of intraoral carcinoma. Surgery 1946; 20:133-46; PMID:20992244.
93. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63:1727-30; PMID:12702551.
94. Dakubo GD, Jakupciak JP, Birch-Machin MA, Parr RL. Clinical implications and utility of field cancerization. Cancer Cell Int 2007; 7:2; PMID:17362521; http://dx.doi.org/10.1186/1475-2867-7-2.
95. Senthil K, Aranganathan S, Nalini N. Evidence of oxidative stress in the circulation of ovarian cancer patients. Clin Chim Acta 2004; 339:27-32; PMID:14687890; http://dx.doi.org/10.1016/j.cccn.2003.08.017.
96. Gallagher SM, Castorino JJ, Wang D, Philp NJ. Monocarboxylate transporter 4 regulates maturation and trafficking of CD147 to the plasma membrane in the metastatic breast cancer cell line MDA-MB-231. Cancer Res 2007; 67:4182-9; PMID:17483329; http://dx.doi.org/10.1158/0008-5472.CAN-06-3184.
97. Martinez-Outschoorn UE, Goldberg A, Lin Z, Ko YH, Flomenberg N, Wang C, et al. Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biol Ther 2011; 12:924-38; PMID:22041887; http://dx.doi.org/10.4161/cbt.12.10.17780.